The programed death‐1/programed death ligand‐1 axis and its potential as a therapeutic target for virus‐associated tumours

Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review

(2023) Ashraf Elbahrawy et al.   Viruses-Basel

PD-L1 upregulation by lytic induction of Epstein-Barr Virus

(2022) Yusuke Yanagi et al.   VIROLOGY

Lymphocytes Infiltration and Expression of PD-1 and PD-L1 in Colorectal Cancer Between HIV-Infected and Non-HIV-Infected Patients: A Propensity Score Matched Cohort Study

(2022) Ye Cao et al.   Frontiers in Oncology

Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142–5p/PD-L1 axis

(2022) Junjun Ling et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

(2022) Qing Tang et al.   Frontiers in Immunology

Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments

(2022) Oren Shechter et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients

(2022) Marwa Hassan et al.   Tumour Virus Research

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

(2021) David Johnson et al.   ORAL ONCOLOGY

CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients

(2021) Katherine Antel et al.   PATHOLOGY

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma

(2021) Kina Kase et al.   Microorganisms

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis

(2021) Andrea Botticelli et al.   Frontiers in Immunology

CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways

(2021) Xiaona Chen et al.   Frontiers in Oncology

Human Papillomaviruses-Associated Cancers: An Update of Current Knowledge

(2021) Ena Pešut et al.   Viruses-Basel

Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

(2020) Ghasem Rahimi Kalateh Shah Mohammad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Profiling global cancer incidence and mortality by socioeconomic development

(2020) Joannie Lortet‐Tieulent et al.   INTERNATIONAL JOURNAL OF CANCER

The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence

(2020) G. Tapia Rico et al.   CANCER TREATMENT REVIEWS

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response

(2020) LanLan Liu et al.   PLoS One

Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression

(2020) Xinxin Yang et al.   Cancer Management and Research

Epstein–Barr virus-associated gastric cancer: A distinct subtype

(2020) Jing Yang et al.   CANCER LETTERS

Human hepatitis viruses-associated cutaneous and systemic vasculitis

(2020) Chrong-Reen Wang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer

(2019) Shahla Bari et al.   Journal of Oncology

OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection

(2019) Felix Johannes Jacobi et al.   JOURNAL OF HEPATOLOGY

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions

(2019) Shulun Chen et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Epstein-Barr virus strain variation and cancer

(2019) Teru Kanda et al.   CANCER SCIENCE

Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer

(2019) Angela M. Hong et al.   ORAL ONCOLOGY

An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma

(2019) Paul G. Murray et al.   BLOOD

TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2

(2019) Paramita Baruah et al.   Frontiers in Immunology

Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion

(2019) Yishuang Sun et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance

(2019) Alessandra Bandera et al.   CURRENT OPINION IN PHARMACOLOGY

Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation

(2019) Jungang Chen et al.   VIROLOGY

New Approaches on Cancer Immunotherapy

(2019) Jong-Ho Cha et al.   Cold Spring Harbor Perspectives in Medicine

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

(2019) Alexandre S. Cristino et al.   BLOOD

Viral Hepatitis

(2019) Simone Lanini et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Epidemiology and burden of HPV-related disease

(2018) Beatriz Serrano et al.   BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY

PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules

(2018) Qiaohong Geng et al.   CURRENT PHARMACEUTICAL DESIGN

Cellular membrane trafficking machineries utilized by the hepatitis viruses

(2018) Jun Inoue et al.   HEPATOLOGY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer

(2018) Lorena Ostios-Garcia et al.   Journal of Thoracic Oncology

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

(2018) Fatemeh K. Dermani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

(2018) Xian Shen et al.   BMJ-British Medical Journal

PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer

(2018) Ying Meng et al.   Journal of Cancer

Evolutionary biology of human hepatitis viruses

(2018) Andrea Rasche et al.   JOURNAL OF HEPATOLOGY

Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy

(2018) Yu-Jen Liu et al.   Cancers

Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity

(2017) Chaoqi Liu et al.   Molecular Medicine Reports

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Human oncogenic viruses: nature and discovery

(2017) Yuan Chang et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Tumour virus epidemiology

(2017) Ruth M. Lunn et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Epstein–Barr virus infection and nasopharyngeal carcinoma

(2017) Sai Wah Tsao et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Deep sequencing in the management of hepatitis virus infections

(2017) Josep Quer et al.   VIRUS RESEARCH

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

(2017) Yajuan Zhou et al.   Scientific Reports

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

(2017) Maria Gato-Cañas et al.   Cell Reports

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Modeling hepatitis virus infections and treatment strategies in humanized mice

(2017) Dina Kremsdorf et al.   Current Opinion in Virology

A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers

(2017) Po-Lin Lin et al.   Cancer Medicine

PD-1/PD-L1 Pathway in Breast Cancer

(2017) Florian Schütz et al.   Oncology Research and Treatment

Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study

(2017) Salvinia Mletzko et al.   OncoImmunology

PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis

(2017) Lihu Gu et al.   PLoS One

Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus–associated gastric carcinoma

(2016) Min Dong et al.   HUMAN PATHOLOGY

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy

(2016) Pashtoon Murtaza Kasi et al.   MEDICAL HYPOTHESES

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

(2016) Ruri Saito et al.   MODERN PATHOLOGY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

The cancer burden attributable to biologic agents

(2015) David Schottenfeld et al.   ANNALS OF EPIDEMIOLOGY

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

PD-1 and PD-L1 blockade in gastrointestinal malignancies

(2015) Hazel Lote et al.   CANCER TREATMENT REVIEWS

Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers

(2015) Louisa Mezache et al.   MODERN PATHOLOGY

PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing

(2015) Ilseyar Akhmetzyanova et al.   PLoS Pathogens

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

Origin of the Transmitted Virus in HIV Infection: Infected Cells Versus Cell-Free Virus

(2014) M. Sagar   JOURNAL OF INFECTIOUS DISEASES

HIV and the spectrum of human disease

(2014) Sebastian Lucas et al.   JOURNAL OF PATHOLOGY

Epstein-Barr Virus Turns 50

(2014) P. M. Lieberman   SCIENCE

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The Five Hepatitis Viruses

(2011) G. J. Ebrahim   JOURNAL OF TROPICAL PEDIATRICS

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

(2011) Zhen Zeng et al.   PLoS One

Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection

(2010) Tao Shen et al.   JOURNAL OF MEDICAL VIROLOGY

Intrahepatic PD-1/PD-L1 Up-regulation Closely Correlates with Inflammation and Virus Replication in Patients with Chronic HBV Infection

(2009) Zhunyi Xie et al.   IMMUNOLOGICAL INVESTIGATIONS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment

(2008) Simona Urbani et al.   JOURNAL OF HEPATOLOGY

Implications of recombination for HIV diversity

(2008) Bertha Cecilia Ramirez et al.   VIRUS RESEARCH